Nek1 and TAZ Interact to Maintain Normal Levels of Polycystin 2
- Authors
- Yim, Hyungshin; Sung, Chang K.; You, John; Tian, Yu; Benjamin, Thomas
- Issue Date
- May-2011
- Publisher
- AMER SOC NEPHROLOGY
- Keywords
- transcription factor; unclassified drug; Phosphorylation; Protein-Serine-Threonine Kinases; protein kinase; negative feedback; mouse; Ubiquitination; TRPP Cation Channels; priority journal; complex formation; Cilia; protein protein interaction; Polycystic
- Citation
- JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, v.22, no.5, pp.832 - 837
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Volume
- 22
- Number
- 5
- Start Page
- 832
- End Page
- 837
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/38108
- DOI
- 10.1681/ASN.2010090992
- ISSN
- 1046-6673
- Abstract
- Polycystic kidney disease (PKD) in mice can arise from defects in Nek kinases, which participate in ciliogenesis. PKD can also arise from loss of the protein TAZ, an adaptor protein in the E3 ubiquitin ligase complex that targets the ciliary protein polycystin 2 (PC2) for degradation, but whether Nek and TAZ contribute to the same biochemical pathway is unknown. Here, we report that the nimA-related protein kinase Nek1 phosphorylates TAZ at a site essential for the ubiquitination and proteasonnal degradation of PC2. Loss of Nek1 leads to underphosphorylation of TAZ, thereby promoting the abnormal accumulation of PC2. Furthermore, TAZ targets Nek1 for degradation. These data suggest that TAZ and Nek1 constitute a negative feedback loop linked through phosphorylation and ubiquitination and that the interaction of Nek1 and TAZ maintain PC2 at the level needed for proper ciliogenesis.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/38108)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.